CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 5.71 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $416.00 thousand by 99.04 percent. This is a 90.70 percent decrease over sales of $43.00 thousand the same period last year.